Description
Eli Lilly Expands Beyond Diabetes—Can New Pain & Liver Therapies Disrupt Traditional Care?
Eli Lilly and Company’s second-quarter 2025 financial results represent a blend of remarkable achievements and strategic foresight, coupled with challenges typical of the pharmaceutical industry. The company reported a robust 38% increase in revenue compared to Q2 2024, driven primarily by key products like Mounjaro, Zepbound, and Verzenio. This outcome highlights the strong demand for its therapies across major therapeutic areas, especially in cardiometabolic health and oncology.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
